EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. PRYMY
5. SKA-B

6. PBA
7. CCH:LN
8. META
9. BAJAJHFL:I
10. CCHGY

Get Alerts EYPT Hot Sheet

Price: $13.98 +5.99%

Overall Analyst Rating:
SELL (= Flat)

EPS Growth %: -10.6%

Join SI Premium – FREE

WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:30 AM ET.

A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company's website at www.eyepoint.com. The replay will be available for 90 days after the event.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert® technology for extended intravitreal drug delivery including EYP-1901, a VEGF inhibitor, targeting wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

ContactsInvestors: Argot PartnersSam Martin or Joe Rayne212-600-1902[email protected]

Media: Thomas Gibson201-476-0322 [email protected]